Your browser doesn't support javascript.
High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts.
Naranbhai, Vivek; Chang, Christina C; Beltran, Wilfredo F Garcia; Miller, Tyler E; Astudillo, Michael G; Villalba, Julian A; Yang, Diane; Gelfand, Jeffrey; Bernstein, Bradley E; Feldman, Jared; Hauser, Blake M; Caradonna, Timothy M; Alter, Galit; Murali, Mandakolathur R; Jasrasaria, Rashmi; Quinlan, Joan; Xerras, Dean C; Betancourt, Joseph R; Louis, David N; Schmidt, Aaron G; Lennerz, Jochen; Poznansky, Mark C; Iafrate, A John.
  • Naranbhai V; Dana Farber Cancer Institute, Boston, Massachusetts, USA.
  • Chang CC; MGH Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Beltran WFG; Department of Medicine, Massachusetts General Hospital, Massachusetts, USA.
  • Miller TE; Centre for the AIDS Programme of Research in South Africa, Durban, KwaZulu Natal, South Africa.
  • Astudillo MG; Centre for the AIDS Programme of Research in South Africa, Durban, KwaZulu Natal, South Africa.
  • Villalba JA; Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Victoria, Australia.
  • Yang D; Therapeutic and Vaccine Research Programme, Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
  • Gelfand J; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Bernstein BE; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Feldman J; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Hauser BM; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Caradonna TM; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Alter G; Department of Medicine, Massachusetts General Hospital, Massachusetts, USA.
  • Murali MR; Vaccine and Immunotherapy Center, Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Jasrasaria R; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Quinlan J; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, Massachusetts, USA.
  • Xerras DC; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, Massachusetts, USA.
  • Betancourt JR; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, Massachusetts, USA.
  • Louis DN; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, Massachusetts, USA.
  • Schmidt AG; Department of Medicine, Massachusetts General Hospital, Massachusetts, USA.
  • Lennerz J; Department of Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Poznansky MC; Department of Medicine, Massachusetts General Hospital, Massachusetts, USA.
  • Iafrate AJ; MGH Chelsea HealthCare Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
J Infect Dis ; 222(12): 1955-1959, 2020 11 13.
Article in English | MEDLINE | ID: covidwho-1024103
ABSTRACT
SARS-CoV-2 antibody testing allows quantitative determination of disease prevalence, which is especially important in high-risk communities. We performed anonymized convenience sampling of 200 currently asymptomatic residents of Chelsea, the epicenter of COVID-19 illness in Massachusetts, by BioMedomics SARS-CoV-2 combined IgM-IgG point-of-care lateral flow immunoassay. The seroprevalence was 31.5% (17.5% IgM+IgG+, 9.0% IgM+IgG-, and 5.0% IgM-IgG+). Of the 200 participants, 50.5% reported no symptoms in the preceding 4 weeks, of which 24.8% (25/101) were seropositive, and 60% of these were IgM+IgG-. These data are the highest seroprevalence rates observed to date and highlight the significant burden of asymptomatic infection.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Point-of-Care Systems / COVID-19 / Antibodies, Viral Type of study: Diagnostic study / Observational study / Prognostic study Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: North America Language: English Journal: J Infect Dis Year: 2020 Document Type: Article Affiliation country: Infdis

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Point-of-Care Systems / COVID-19 / Antibodies, Viral Type of study: Diagnostic study / Observational study / Prognostic study Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: North America Language: English Journal: J Infect Dis Year: 2020 Document Type: Article Affiliation country: Infdis